Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FX06

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FX06

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Assistance Publique Hopitaux de Paris

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020


            Company has announced that the randomized, double-blind, placebo-controlled FX-COVID trial which is conducted by AP-HP (Assistance Publique – Hopitaux de Paris), is set up to confirm the efficacy and safety of FX06 in hospitalized patients receiving mechanical ventilation.